Clinical Efficacy of Second-generation Tyrosine Kinase Inhibitor in Treating Chronic Myeloid Leukemia

Objective To evaluate the efficacy of second-generation tyrosine kinase inhibitor (TKI) in treating chronic myeloid leukemia (CML). Methods A total of 97 patients with CML were enrolled. The patients were treated with TKI and monitored with complete blood count, cytogenetic and molecular indicators during the course of therapy. Survival analysis was performed to evaluate its clinical efficacy. Results The treatment achieved 97.9% complete hematologic response (CHR), 63.9% major cytogenetic response (MCyR), 60.0% complete cytogenetic response (CCyR) and 44.3% major molecular response (MMR) rates. Apart from CHR, better effects were shown in those indicators during chronic phase compared with progressive phase ( P＜0.05). The 1-year, 2-year, 3-year and 5-year overall survival (OS) rate was (90.6±3.0)%, (80.1±4.5)%, (77.5±5.0)% and (64.6±9.3)%, respectively, compared with an event-free survival (EFS) rate of (81.1±4.0)%, (64.4±5.3)%, (56.4±6.0)% and (46.2±8.2)%, respectively. The patients had a 1-year, 2-year, 3-year and 5-year progession-free survival (PFS) rate of (87.4±3.4)%, (73.2±4.9)%, (68.9±5.5)% and (57.4±8.7)%, respectively. A difference between chronic phase (better results) and progressive phase ( P＜0.05) was also found in survival indicators. The first-line TKI therapy had 100% CHR, 95% MCyR, 95% CCyR and 70% MMR, compared with 97.3% CHR, 56.8% MCyR, 48.6% CCyR and 36.5% MMR for the second-line TKI therapy. Apart from CHR, the first-line therapy produced better results than the seond-line therapy ( P＜0.05) . Conclusion CML patients in chronic phase and first-line use of TKI have better outcomes.